FGF21 modulates immunometabolic homeostasis via the ALOX15/15-HETE axis in early liver graft injury
Xinyu Yang, Hao Chen, Wei Shen, Yuanming Chen, Zuyuan Lin, Jianyong Zhuo, Shuai Wang, Modan Yang, Huigang Li, Chiyu He, Xuanyu Zhang, Zhihang Hu, Zhengxing Lian, Mengfan Yang, Rui Wang, Changbiao Li, Binhua Pan, Xu Li, Jun Chen, Xuyong Wei, Qiang Wei, Haiyang Xie, Shusen Zheng, Di Lu, Xiao Xu
Abstract
Fibroblast growth factor 21 (FGF21) is essential for modulating hepatic homeostasis, but the impact of FGF21 on liver graft injury remains uncertain. Here, we show that high FGF21 levels in liver graft and serum are associated with improved graft function and survival in liver transplantation (LT) recipients. FGF21 deficiency aggravates early graft injury and activates arachidonic acid metabolism and regional inflammation in male mouse models of hepatic ischemia/reperfusion (I/R) injury and orthotopic LT. Mechanistically, FGF21 deficiency results in abnormal activation of the arachidonate 15-lipoxygenase (ALOX15)/15-hydroxy eicosatetraenoic acid (15-HETE) pathway, which triggers a cascade of innate immunity-dominated pro-inflammatory responses in grafts. Notably, the modulating role of FGF21/ALOX15/15-HETE pathway is more significant in steatotic livers. In contrast, pharmacological administration of recombinant FGF21 effectively protects against hepatic I/R injury. Overall, our study reveals the regulatory mechanism of FGF21 and offers insights into its potential clinical application in early liver graft injury after LT. Marginal liver grafts are associated with a higher risk of graft failure due to their increased susceptibility to ischemia-reperfusion injury. Here, the authors show the regulatory mechanism of fibroblast growth factor 21 and offer insights into its clinical application in early liver graft injury.